DUBLIN--(BUSINESS WIRE )--The "Cardiovascular Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Device and Application" report has been added to ResearchAndMarkets.com's offering.

The cardiovascular devices market is expected to grow from US$ 48,106.47 million in 2021 to US$ 76,526.68 million in 2028; it is estimated to grow at a CAGR of 6.9% from 2021 to 2028.

The growth of the market is due to the increasing prevalence of cardiovascular diseases and the rising number of product launches & approvals. However, the high cost of products and procedures is expected to restrict the market growth during the forecast period. Cardiovascular diseases (CVDs) are likely to remain the largest cause of morbidity and mortality globally.

CVDs are disorders of the heart and blood vessels and lead to several medical conditions, such as cerebrovascular disease, coronary heart disease, and rheumatic heart disease. A few of the major lifestyle factors that lead to CVDs and difficulties are tobacco use, unhealthy diet, and physical inactivity, which increases the risk of heart attacks and strokes. .

The comparative company analysis evaluates and categorizes the cardiovascular devices market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion) and geographic presence that aids businesses in better decision making and understanding the competitive landscape.

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the global cardiovascular devices market, including Boston Scientific Corporation; Medtronic; GE Healthcare; Koninklijke Philips N.V.; Siemen Healthineers; Abbott; Johnson and Johnson Services, Inc.; B. Braun Melsungen; BD; and Edwards Lifesciences Corporation.

The key company initiating a distinct growth strategy will have a high potential to grow the global cardiovascular devices market. The above data signifies the recent development activities and the presence of robust companies in their respective field. Competitive growth strategies in terms of markets help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects.

It represents continuous merger and acquisition strategy, geographical expansion, research and development, and optimal or advantageous suitability for adopting new product launch strategies for further business expansion and growth during the forecast period. Thus, start-ups are contributing significantly to the cardiovascular devices market growth

A few of the significant developments by key players

In January 2021, Medtronic plc announced the launch of its MyCareLink Heartmobile app to support the world's first and only portfolio of pacemakers that can communicate directly with patients' smartphones and tablets. It is compatible with Medtronic BlueSync technology-enabled pacemakers. The MyCareLink Heart mobile app is designed to securely and wirelessly send device data to the Medtronic CareLink network via smart technology, eliminating the need for a dedicated bedside monitor or other remote monitoring hardware.

In June 2021, Abbott announced the US launch of Jot Dx, the company's latest insertable cardiac monitor (ICM). Jot Dx ICM is supported by SyncUP, a personalized service that delivers one-on-one training and education to help patients connect and stay connected to their ICM.

In September 2021, Abbott announced that it has planned to acquire Cephea Valve Technologies, Inc. The acquisition is likely to strengthen Abbott's structural heart portfolio.

In January 2022, Medtronic announced that it would acquire cardiac mapping and ablation technology developer Affera. The company expects the transaction to close in the first half of 2023.

In February 2022, Abbott announced that the US Food and Drug Administration (FDA) had approved an expanded indication for the company's CardioMEMS HF System to support the care of more people living with heart failure. The sensor provides an early warning system enabling doctors to protect against worsening heart failure.

2. Global Cardiovascular Devices Market - Key Takeaways

4. Cardiovascular Devices Market - Market Landscape

5. Cardiovascular Devices Market - Key Market Dynamics

5.1.1 Increasing Prevalence of Cardiovascular Diseases

5.1.2 Rising Number of Product Launches and Approvals

5.2.1 High Cost of Products and Procedures

5.3.1 Untapped Potential of Emerging Economies

6. Cardiovascular Devices Market- Global Analysis

6.1 Cardiovascular Devices Market Revenue Forecast and Analysis

6.1.1 Cardiovascular Devices Market Revenue Forecast and Analysis

6.1.2 Global Cardiovascular Devices Market Revenue Forecast and Analysis

6.1.3 Global Cardiovascular Devices Market - Market Potential Analysis, By Region

7. Cardiovascular Devices Market Analysis - By Device

7.2 Cardiovascular Devices Market Revenue Share, by Device (2021 & 2028)

8. Cardiovascular Devices Market-Analysis and Forecasts To 2028 - Application

8.2 Global Cardiovascular Devices Market Share By Application 2021 & 2028 (%)

9. Cardiovascular Devices Market-Analysis and Forecasts To 2028 - End User

9.2 Global Cardiovascular Devices Market Share by End User 2021 & 2028 (%)

10. Global Cardiovascular Devices Market - Geographic Analysis

11. Impact of COVID-19 Pandemic on Global Cardiovascular Devices Market

11.1 North America: Impact Assessment of COVID-19 Pandemic

11.2 Europe: Impact Assessment of COVID-19 Pandemic

11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic

11.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic

11.5 South & Central America: Impact Assessment of COVID-19 Pandemic

12. Cardiovascular Devices Market -Industry Landscape

12.2 Growth Strategies in the Cardiovascular Devices Market, 2021-2028

For more information about this report visit https://www.researchandmarkets.com/r/ifve3u

ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900